<DOC>
	<DOCNO>NCT02737046</DOCNO>
	<brief_summary>The investigator propose use Belinostat combination AZT consolidation therapy treatment ATLL .</brief_summary>
	<brief_title>Belinostat Therapy With Zidovudine Adult T-Cell Leukemia-Lymphoma</brief_title>
	<detailed_description>ATLL aggressive malignancy cause HTLV-1 . ATLL cure conventional chemotherapy thus urge development new therapeutic strategy . HDAC inhibitor broadly active anti-neoplastic agent exploit treatment ATLL demonstrate pharmacologic inhibition HDACs promote acetylation nucleosomes chromatin unwinding HTLV-1 5 ' LTR , result transcription viral genome . Belinostat , potent pan HDAC inhibitor , cause H3 subunit acetylation induce HTLV-1 Tax expression culture ATLL cell result dose-dependent apoptosis . Further , Belinostat block constitutive expression NF-κB , increase apoptosis presence AZT .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Belinostat</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>1 . Histologically cytologically document adult Tcell leukemia/lymphoma ( ATLL ) follow characteristic : stage disease , aggressive leukemic type ( unfavorable chronic acute ) initial absolute lymphocytosis ≥ 4.0 cells/mm3 upon initial disease presentation , document presence ATLL cell peripheral blood either morphology , histology , flow cytometry gene rearrangement study 2 . One following : Received prior zidovudine/interferon alfa therapy ( AZT/IFNα ) therapy ≥2 week achieve least partial hematological response define &gt; 50 % reduction absolute lymphocyte count ) without evidence new disease lesion disease progression ( defined 50 % increase measurable disease nadir section 14.5 imaging perform ) time enrollment OR , receive chemotherapy ≥ 2 week duration , follow least partial hematologic response ( ( define &gt; 50 % reduction absolute lymphocyte count ) , without evidence new disease lesion disease progression ( defined 50 % increase absolute lymphocyte count measurable disease nadir specify section 14.5 imaging perform ) time enrollment . 3 . Presence residual ATLL base Tcell clonality peripheral blood time enrollment 4 . Documented Human Tcell lymphotropic virus type 1 ( HTLV1 ) infection : Documentation may serologic assay ( ELISA ) confirm Western blot polymerase chain reaction ( PCR ) . 5 . Measurable evaluable disease . 6 . 18 year age old . 7 . Karnofsky performance status ( KPS ) ≥ 50 % Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 8 . Patients must adequate end organ bone marrow function define : absolute neutrophil count ( ANC ) ≥ 1,000 cells/mm3 [ Exception : Unless cytopenia secondary ATLL ] platelet ( PLT ) ≥ 50,000 cells/mm3 [ Exception : Unless cytopenia secondary ATLL ] Adequate hepatic function : transaminase ≤ 2.5 institutional upper limit normal ( ULN ) , total bilirubin ≤ 1.5 x institutional upper limit normal ( ULN ) , [ Exception : Unless secondary hepatic infiltration lymphoma . If elevate bilirubin felt secondary Indinavir Atazavinir therapy ( antiHIV medication ) , patient allow enroll . ] Creatinine clearance ( CrCl ) ≥ 40 mL/min , [ Exception : Unless secondary renal involvement lymphoma . ] 9 . Patients human immunodeficiency virus positive ( HIV+ ) also eligible . 10 . Females childbearing potential ( CBP ) must negative serum pregnancy test within one week enrollment . Women avoid pregnancy receive study treatment . Males female must agree use adequate birth control participation trial 3 month complete therapy . 11 . Patients receive erythropoietin Granulocytecolony stimulating factor ( GCSF ) baseline eligible . 12 . Ability understand willingness sign write informed consent document . 1 . Patients progressive disease ( previous chemotherapy AZT/IFNα ) time enrollment . 2 . Patients lymphomatous , chronic leukemia favorable feature , smolder type ATLL ( definition ATLL subtypes see Appendix H ) . 3 . Patients receive investigational agent within 14 day prior initiation study therapy . ( Exception : Patients actively receive IFNalfa2b PEGIFNalfa2b permit ) . 4 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure ( CHF ) , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation likely judgment Investigator ( ) interfere limit compliance study requirements/treatment . 5 . Pregnant breastfeed woman . 6 . Known hypersensitivity histone deacetylases ( HDACs ) , zidovudine , belinostat component formulation ( ) . 7 . Autoimmune viral hepatitis decompensated liver disease unless due lymphoma . 8 . Concurrent active malignancy , exception situ carcinoma cervix , nonmetastatic , nonmelanomatous skin cancer , Kaposi 's sarcoma require systemic chemotherapy . 9 . New York Heart Association ( NYHA ) Class 3 4 heart disease per Appendix D. 10 . Ejection fraction &lt; 50 % 11 . Psychological , familial , sociological geographical condition likely judgment Investigator ( ) interfere limit compliance study requirements/treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Adult T-cell Leukemia-Lymphoma</keyword>
	<keyword>ATLL</keyword>
</DOC>